search for




 

Review Article
Management of Hepatoblastoma in the Modern Era and Future Perspectives
Clin Pediatr Hematol Oncol 2020;27:43-54.
Published online April 30, 2020
© 2020 Korean Society of Pediatric Hematology-Oncology

Jin Kyung Suh, Sunghan Kang, Hyery Kim, Kyung-Nam Koh and Ho Joon Im

Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to: Kyung-Nam Koh
Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center Children’s Hospital, University of Ulsan College of Medicine, 88 Olympic-ro, 43-gil, Songpa-gu, Seoul 05505, Korea
Tel: +82-2-3010-5994
Fax: +82-2-473-3725
E-mail: pedkkn@amc.seoul.kr
ORCID ID: orcid.org/0000-0002-6376-672X
Received April 4, 2020; Revised April 14, 2020; Accepted April 14, 2020.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Hepatoblastoma is the most common malignant hepatic tumor in infants and young children and accounts for approximately 1% of all pediatric malignancies. A treatment strategy incorporating chemotherapy and surgical resection has evolved based on the results of the multicenter clinical trials performed by the major liver study groups during the last two decades and led to significantly improved survival outcomes. The alpha-fetoprotein level, PRE-Treatment EXTent tumor stage, and histological category are well-known prognostic factors that are used for risk stratification. Platinum-based chemotherapy regimens are effective in terms of increasing the likelihood of surgical resectability. Refinement of surgical techniques and the advent of liver transplantation have improved the outcomes in patients with advanced tumors. However, the optimal treatment strategy for advanced hepatoblastoma remains unclear. Unanswered questions include the optimal timing and indications for pulmonary metastasectomy and when the surgical strategy should be complex liver resection or liver transplantation. The major liver study groups have now formed a global coalition known as the Children’s Hepatic tumors International Collaboration and developed an international staging system. The aim of this article is to review current treatment strategies of hepatoblastoma focusing on high risk patients.
Keywords: Hepatoblastoma, Risk stratification, Chemotherapy, Surgical resection
References
  1. Spector LG, Birch J. The epidemiology of hepatoblastoma. Pediatr Blood Cancer 2012;59:776-9.
    Pubmed CrossRef
  2. Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014;26:19-28.
    Pubmed CrossRef
  3. Gregory JJ Jr, Finlay JL. Alpha-fetoprotein and beta-human chorionic gonadotropin: their clinical significance as tumour markers. Drugs 1999;57:463-7.
    Pubmed CrossRef
  4. Koh KN, Park M, Kim BE, et al. Prognostic implications of serum alpha-fetoprotein response during treatment of hepatoblastoma. Pediatr Blood Cancer 2011;57:554-60.
    Pubmed CrossRef
  5. Uchida H, Sakamoto S, Sasaki K, et al. Surgical treatment strategy for advanced hepatoblastoma: resection versus transplantation. Pediatr Blood Cancer 2018;65:e27383.
    Pubmed CrossRef
  6. Maibach R, Roebuck D, Brugieres L, et al. Prognostic stratification for children with hepatoblastoma: the SIOPEL experience. Eur J Cancer 2012;48:1543-9.
    Pubmed CrossRef
  7. Kremer N, Walther AE, Tiao GM. Management of hepatoblastoma:an update. Curr Opin Pediatr 2014;26:362-9.
    Pubmed CrossRef
  8. Towbin AJ, Meyers RL, Woodley H, et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 2018;48:536-54.
    Pubmed CrossRef
  9. Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM, Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer 2009;53:1016-22.
    Pubmed KoreaMed CrossRef
  10. Perilongo G, Shafford E, Maibach R, et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. Eur J Cancer 2004;40:411-21.
    Pubmed CrossRef
  11. Roebuck DJ, Aronson D, Clapuyt P, et al. 2005 PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol 2007;37:123-32; quiz 249-50.
    Pubmed KoreaMed CrossRef
  12. Angelico R, Grimaldi C, Gazia C, et al. How do synchronous lung metastases influence the surgical management of children with hepatoblastoma? An update and systematic review of the literature. Cancers (Basel) 2019;11.
    Pubmed KoreaMed CrossRef
  13. Meyers RL, Tiao G, de Ville de Goyet J, Superina R, Aronson DC. Hepatoblastoma state of the art: pre-treatment extent of disease, surgical resection guidelines and the role of liver transplantation. Curr Opin Pediatr 2014;26:29-36.
    Pubmed CrossRef
  14. Lovvorn HN 3rd, Ayers D, Zhao Z, et al. Defining hepatoblastoma responsiveness to induction therapy as measured by tumor volume and serum alpha-fetoprotein kinetics. J Pediatr Surg 2010;45:121-8; discussion 9.
    Pubmed KoreaMed CrossRef
  15. Czauderna P, Otte JB, Aronson DC, et al. Guidelines for surgical treatment of hepatoblastoma in the modern era--recommendations from the Childhood Liver Tumour Strategy Group of the International Society of Paediatric Oncology (SIOPEL). Eur J Cancer 2005;41:1031-6.
    Pubmed CrossRef
  16. Meyers RL, Tiao GM, Dunn SP, Langham MR Jr. Liver transplantation in the management of unresectable hepatoblastoma in children. Front Biosci (Elite Ed) 2012;4:1293-302.
    Pubmed CrossRef
  17. Madanur MA, Battula N, Davenport M, Dhawan A, Rela M. Staged resection for a ruptured hepatoblastoma: a 6-year follow-up. Pediatr Surg Int 2007;23:609-11.
    Pubmed CrossRef
  18. Meyers RL, Maibach R, Hiyama E, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children’s Hepatic tumors International Collaboration. Lancet Oncol 2017;18:122-31.
    Pubmed KoreaMed CrossRef
  19. Czauderna P, Haeberle B, Hiyama E, et al. The Children’s Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 2016;52:92-101.
    Pubmed KoreaMed CrossRef
  20. Meyers RL, Czauderna P, Otte JB. Surgical treatment of hepatoblastoma. Pediatr Blood Cancer 2012;59:800-8.
    Pubmed CrossRef
  21. Otte JB, Pritchard J, Aronson DC, et al. Liver transplantation for hepatoblastoma: results from the International Society of Pediatric Oncology (SIOP) study SIOPEL-1 and review of the world experience. Pediatr Blood Cancer 2004;42:74-83.
    Pubmed CrossRef
  22. Pham TA, Gallo AM, Concepcion W, Esquivel CO, Bonham CA. Effect of liver transplant on long-term disease-free survival in children with hepatoblastoma and hepatocellular cancer. JAMA Surg 2015;150:1150-8.
    Pubmed CrossRef
  23. Otte JB, Meyers RL, de Ville de Goyet J. Transplantation for liver tumors in children: time to (re)set the guidelines? Pediatr Transplant 2013;17:710-2.
    Pubmed CrossRef
  24. Fuchs J, Cavdar S, Blumenstock G, et al. POST-TEXT III and IV hepatoblastoma: extended hepatic resection avoids liver transplantation in selected cases. Ann Surg 2017;266:318-23.
    Pubmed CrossRef
  25. Lautz TB, Ben-Ami T, Tantemsapya N, Gosiengfiao Y, Superina RA. Successful nontransplant resection of POST-TEXT III and IV hepatoblastoma. Cancer 2011;117:1976-83.
    Pubmed CrossRef
  26. Kubota M, Yagi M, Kanada S, et al. Effect of postoperative chemotherapy on the serum alpha-fetoprotein level in hepatoblastoma. J Pediatr Surg 2004;39:1775-8.
    Pubmed CrossRef
  27. Moon SB, Shin HB, Seo JM, Lee SK. Hepatoblastoma: 15-year experience and role of surgical treatment. J Korean Surg Soc 2011;81:134-40.
    Pubmed KoreaMed CrossRef
  28. Czauderna P, Garnier H. Hepatoblastoma: current understanding, recent advances, and controversies. F1000Res 2018;7:53.
    Pubmed KoreaMed CrossRef
  29. Otte JB, de Ville de Goyet J, Reding R. Liver transplantation for hepatoblastoma: indications and contraindications in the modern era. Pediatr Transplant 2005;9:557-65.
    Pubmed CrossRef
  30. Meyers RL, Katzenstein HM, Krailo M, McGahren ED 3rd, Malogolowkin MH. Surgical resection of pulmonary metastatic lesions in children with hepatoblastoma. J Pediatr Surg 2007;42:2050-6.
    Pubmed CrossRef
  31. Ruth ND, Kelly D, Sharif K, Morland B, Lloyd C, McKiernan PJ. Rejection is less common in children undergoing liver transplantation for hepatoblastoma. Pediatr Transplant 2014;18:52-7.
    Pubmed CrossRef
  32. Perilongo G, Brown J, Shafford E, et al. Hepatoblastoma presenting with lung metastases: treatment results of the first cooperative, prospective study of the International Society of Paediatric Oncology on childhood liver tumors. Cancer 2000;89:1845-53.
    Pubmed CrossRef
  33. Brown J, Perilongo G, Shafford E, et al. Pretreatment prognostic factors for children with hepatoblastoma--results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer 2000;36:1418-25.
    Pubmed CrossRef
  34. O’Neill AF, Towbin AJ, Krailo MD, et al. Characterization of pulmonary metastases in children with hepatoblastoma treated on Children’s Oncology Group Protocol AHEP0731 (the treatment of children with all stages of hepatoblastoma): A report from the Children’s Oncology Group. J Clin Oncol 2017;35:3465-73.
    Pubmed KoreaMed CrossRef
  35. Zsiros J, Brugieres L, Brock P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with highrisk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study. Lancet Oncol 2013;14:834-42.
    Pubmed KoreaMed CrossRef
  36. Hishiki T, Watanabe K, Ida K, et al. The role of pulmonary metastasectomy for hepatoblastoma in children with metastasis at diagnosis: Results from the JPLT-2 study. J Pediatr Surg 2017;52:2051-5.
    Pubmed CrossRef
  37. Wanaguru D, Shun A, Price N, Karpelowsky J. Outcomes of pulmonary metastases in hepatoblastoma--is the prognosis always poor? J Pediatr Surg 2013;48:2474-8.
    Pubmed CrossRef
  38. Yang T, Whitlock RS, Vasudevan SA. Surgical management of hepatoblastoma and recent advances. Cancers (Basel) 2019;11.
    Pubmed KoreaMed CrossRef
  39. Urla C, Seitz G, Tsiflikas I, et al. Simultaneous resection of high-risk liver tumors and pulmonary metastases in children. Ann Surg 2015;262:e1-3.
    Pubmed CrossRef


April 2020, 27 (1)
Full Text PDF
Citation
Send to a friend
Twitter
Facebook

Cited By Articles
  • CrossRef (0)

Author ORCID Information
  • Kyung-Nam Koh